I am Associate Professor of Neurology at Georgetown University Medical Center (GUMC) and director of the Translational Neurotherapeutics Program and the Laboratory for Dementia and Parkinsonism.. I am Principal Investigator of the GUMC Lewy Body Dementia Association (LBDA) Research Center of Excellence. I am co-founder and director of the Scientific Advisory Board of KeiferX, a biopharmaceutical company that aims to develop several targeted therapies for neurodegenerative diseases (https://www.keiferx.com). I have extensive drug development and biomarker discovery experience and I currently have advisory roles in pharmaceutical and biotech companies, including Sun Pharma and SkyBio LLC. I am a translational neuroscientist focused on the role of tyrosine kinases and de-ubiquitinases on protein ubiquitination and proteasome-autophagy clearance. I developed several tyrosine kinase inhibitors (TKIs) and de-ubiquitinase inhibitors that are being investigated as potential therapies for neurodegenerative diseases. I have discovered the potential use and conducted clinical trials investigating cancer drugs nilotinib (Abl/DDR inhibitor) and bosutinib (Src/Abl Inhibitor) in neurodegenerative diseases and identified potential novel drug targets, including discoidin domain receptor (DDR) and ubiquitin specific protease USP)-13 that induce autophagy, eliminate inflammation and preserve blood brain barrier integrity. I am a clinical trialist with extensive expertise in design, execution and regulatory science of IND-enabling studies and Phase I-III clinical trials in neurodegenerative diseases. I consulted broadly on medical, scientific and regulator affairs.